Evidence Table I2: DISCRETE outcomes for class ANTI-BACTERIAL (ORAL)./KERATOLYTIC (TOPICAL).

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
	I.01.01			**Sulfur-resorcinol + cotrimoxazole**	**Placebo + cotrimoxazole**	
126 ↑ Parallel N=211		**Severity change (severity)**	Short (5.	Very good (>75% reduction) 7 Good (50-75% reduction) 15 Moderate (25-49% reduction) 24 Poor (<25% reduction) 8	Very good (>75% reduction) 2 Good (50-75% reduction) 6 Moderate (25-49% reduction) 16 Poor (<25% reduction) 12	**0.001**
		Comedones change (count)	Mid (7)	No change/worse 4 Very good + good (>50%) 23 Less than very good improved (50%) 29	No change/worse 12 Very good + good (>50%) 6 Less than very good improved (50%) 34	**0.001**
		Desquamation	Mid (7)	Absent 52 Slight 18 Moderate 1 Withdraw 0	Absent 57 Slight 14 Moderate 0 Withdraw 0	
		Erythema	Mid (7)	Absent 39 Slight 15 Moderate 6 Withdraw 5	Absent 47 Slight 2 Moderate 2 Withdraw 0	
		Papules change (count)	Mid (7)	Very good + good improved (>50%) 22 Less than very good (<50%) 30	Very good + good improved (>50%) 6 Less than very good (<50%) 31	**0.001**
		Pustules change (count)	Mid (7)	Very good + good (>50%) 26 Less than very good improved (<50%) 26	Very good + good (>50%) 19 Less than very good improved (<50%) 18	**NS**
		Severity change (severity)	Mid (7)	Very good (>75% reduction) 8 Good (50-75% reduction) 24 Moderate (25-49% reduction) 15 Poor (1-24% reduction) 16	Very good (>75% reduction) 4 Good (50-75% reduction) 5 Moderate (25-49% reduction) 20 Poor (1-24% reduction) 20	**0.001**
				Unchanged (0% reduction) 4 Worse (<0% reduction) 4	Unchanged (0% reduction) 17 Worse (<0% reduction) 5	
	I.01.02			**Sulfur-resorcinol + cotrimoxazole**	**Tretinoin + cotrimoxazole**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
126 ↑ Parallel N=211		**Severity change (severity)**	Short (5.	Very good (>75% reduction) 7 Good (50-75% reduction) 15 Moderate (25-49% reduction) 24 Poor (<25% reduction) 8	Very good (>75% reduction) 20 Good (50-75% reduction) 22 Moderate (25-49% reduction) 12 Poor (<25% reduction) 8	**0.001**
		Comedones change (count)	Mid (7)	No change/worse 4 Very good + good (>50%) 23 Less than very good improved (50%) 29	No change/worse 1 Very good + good (>50%) 42 Less than very good improved (50%) 17	**0.001**
		Desquamation	Mid (7)	Absent 52 Slight 18 Moderate 1 Withdraw 0	Absent 33 Slight 21 Moderate 14 Withdraw 0	
		Erythema	Mid (7)	Absent 39 Slight 15 Moderate 6 Withdraw 5	Absent 17 Slight 34 Moderate 24 Withdraw 19	
		Papules change (count)	Mid (7)	Very good + good improved (>50%) 22 Less than very good (<50%) 30	Very good + good improved (>50%) 41 Less than very good (<50%) 18	**0.001**
		Pustules change (count)	Mid (7)	Very good + good (>50%) 26 Less than very good improved (<50%) 26	Very good + good (>50%) 44 Less than very good improved (<50%) 15	**NS**
		Severity change (severity)	Mid (7)	Very good (>75% reduction) 8 Good (50-75% reduction) 24 Moderate (25-49% reduction) 15 Poor (1-24% reduction) 16	Very good (>75% reduction) 32 Good (50-75% reduction) 17 Moderate (25-49% reduction) 7 Poor (1-24% reduction) 10	**0.001**
				Unchanged (0% reduction) 4 Worse (<0% reduction) 4	Unchanged (0% reduction) 1 Worse (<0% reduction) 2	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.